PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23418614-11	2013	Staining for Annexin V/propidium iodide and active caspases showed an increase in double-positive cells and the absence of caspase activation following treatment, indicating that LeTx-induced cell death is caspase-independent and nonapoptotic.	letx	179-183	annexin A5	Homo sapiens	13-22
23418614-13	2013	Furthermore, we have demonstrated that LeTx-induced cytotoxicity in AML cells is nonapoptotic and dependent on phospho-ERK1/2 levels.	letx	39-43	mitogen-activated protein kinase 3	Homo sapiens	119-125
18172299-5	2008	Western blotting showed that the phosphorylation levels of ERK, c-Jun-NH(2) kinase, and p38 MAPK decreased after 72 h of LeTx treatment.	letx	121-125	mitogen-activated protein kinase 1	Homo sapiens	59-62
21365009-4	2011	Surprisingly, ERK activity persisted in LeTx-treated cells expressing MEK2cr but not MEK1cr.	letx	40-44	mitogen-activated protein kinase 1	Homo sapiens	14-17
21365009-4	2011	Surprisingly, ERK activity persisted in LeTx-treated cells expressing MEK2cr but not MEK1cr.	letx	40-44	mitogen-activated protein kinase kinase 2	Homo sapiens	70-74
17908989-6	2007	Treatment with LeTx also blocked the ability of these cells to release several angioproliferative cytokines, notably vascular endothelial growth factor (VEGF).	letx	15-19	vascular endothelial growth factor A	Homo sapiens	117-151
17951252-8	2007	Furthermore, pretreatment with LeTx or the GSK3-specific inhibitor SB-216763, or transfection with dominant active mutant Akt or degradation-defected mutant cyclin D1 protected cells from LeTx-induced cell cycle arrest, on-going MEK1 cleavage and suppression of TNF production.	letx	188-192	AKT serine/threonine kinase 1	Homo sapiens	122-125
17951252-8	2007	Furthermore, pretreatment with LeTx or the GSK3-specific inhibitor SB-216763, or transfection with dominant active mutant Akt or degradation-defected mutant cyclin D1 protected cells from LeTx-induced cell cycle arrest, on-going MEK1 cleavage and suppression of TNF production.	letx	188-192	cyclin D1	Homo sapiens	157-166
17951252-8	2007	Furthermore, pretreatment with LeTx or the GSK3-specific inhibitor SB-216763, or transfection with dominant active mutant Akt or degradation-defected mutant cyclin D1 protected cells from LeTx-induced cell cycle arrest, on-going MEK1 cleavage and suppression of TNF production.	letx	188-192	mitogen-activated protein kinase kinase 1	Homo sapiens	229-233
17951252-8	2007	Furthermore, pretreatment with LeTx or the GSK3-specific inhibitor SB-216763, or transfection with dominant active mutant Akt or degradation-defected mutant cyclin D1 protected cells from LeTx-induced cell cycle arrest, on-going MEK1 cleavage and suppression of TNF production.	letx	188-192	tumor necrosis factor	Homo sapiens	262-265
24478317-4	2014	LeTx challenge resulted in transient increase in serum PAF levels and a concurrent decrease in PAF acetylhydrolase activity.	letx	0-4	patchy fur	Mus musculus	95-98
12864812-8	2003	Differential expression of microtubule-associating proteins and a decrease in the level of cellular tubulin were detected in LeTx-treated cells, both of which can result from loss of GSK-3beta activity.	letx	125-129	glycogen synthase kinase 3 beta, genome duplicate a	Danio rerio	183-192
28509866-6	2017	The HDAC8-specific activator TM-2-51 and inhibitor PCI-34051 enhanced and prevented, respectively, AKT activation and cell cycle progression in LeTx-treated cells.	letx	144-148	histone deacetylase 8	Homo sapiens	4-9
28509866-8	2017	Importantly, the JMJD3-specific inhibitor GSK-J4 induced AKT activation and protected cell cycle arrest in LeTx-treated cells, regardless the presence of HDAC8 activity.	letx	107-111	lysine demethylase 6B	Homo sapiens	17-22
24478317-4	2014	LeTx challenge resulted in transient increase in serum PAF levels and a concurrent decrease in PAF acetylhydrolase activity.	letx	0-4	patchy fur	Mus musculus	55-58
24478317-5	2014	Inhibition of PAF activity using PAF antagonists or toxin challenge of PAF receptor negative mice reversed or ameliorated many of the pathologic features of LeTx-induced damage, including changes in vascular permeability, hepatic necrosis, and cellular apoptosis.	letx	157-161	patchy fur	Mus musculus	14-17
24478317-5	2014	Inhibition of PAF activity using PAF antagonists or toxin challenge of PAF receptor negative mice reversed or ameliorated many of the pathologic features of LeTx-induced damage, including changes in vascular permeability, hepatic necrosis, and cellular apoptosis.	letx	157-161	patchy fur	Mus musculus	33-36
24478317-5	2014	Inhibition of PAF activity using PAF antagonists or toxin challenge of PAF receptor negative mice reversed or ameliorated many of the pathologic features of LeTx-induced damage, including changes in vascular permeability, hepatic necrosis, and cellular apoptosis.	letx	157-161	platelet-activating factor receptor	Mus musculus	71-83
24492532-5	2014	Notably, LeTx-induced inflammasome activation is associated with caspase-1 ubiquitination, which is unaffected in ASC-deficient cells.	letx	9-13	caspase 1	Mus musculus	65-74